what are the benefits of the shingles vaccine for a healthy 66year old nale

The short version: the shingles vaccine cuts your chance of getting shingles by about half to three-quarters, but the absolute risk for a healthy 66-year-old man is lower than the marketing suggests.

For a healthy 66-year-old man, the main benefit of the recombinant shingles vaccine (Shingrix) is a lower chance of getting herpes zoster and its most common complication, postherpetic neuralgia (PHN), the nerve pain that can last for months. The best trial data comes from the ZOE-50 and ZOE-70 studies, which were funded by the manufacturer (GSK). In those trials, two doses of Shingrix reduced the incidence of shingles by about 97% in people aged 50 and older, and by about 90% in those 70 and older [1, 4]. Protection against PHN was around 91% [4]. Real-world data from a large Medicare study, however, found lower effectiveness: about 70% after two doses in people 65 and older [1]. That gap between trial and real-world numbers is common and matters.

Here is what that means in absolute terms for a man your age. The table below puts the numbers side by side.

The risk of shingles itself is real but not overwhelming. For a 66-year-old man, the annual chance of getting it is roughly 6 to 7 in 1,000 [2, 3]. The vaccine drops that to about 2 in 1,000. That means about 200 healthy men his age would need to be vaccinated to prevent one case of shingles per year. The vaccine also comes with trade-offs. In the trials, injection-site reactions (pain, redness, swelling) were common, affecting about 8 in 10 people, and systemic reactions like fever or muscle aches affected about half [1, 5]. These are usually short-lived, lasting a day or two. There is also a small but real signal for Guillain-Barré syndrome: about 3 extra cases per million doses within 42 days of vaccination [1].

The evidence does not include long-term safety data beyond about 10 years, and the trials were all funded by the manufacturer. The most informative comparison — vaccinated versus never-vaccinated over many years — has not been run in a way that would catch rare or delayed harms. For a healthy 66-year-old man, the vaccine reduces a modest risk further, but the benefit is not large in absolute terms, and the decision depends on how much you value avoiding a painful but uncommon illness versus accepting a small chance of a serious side effect.

My call: the vaccine reduces shingles risk by about 70% in the real world, but the absolute benefit is small — about 5 fewer cases per 1,000 people per year — and the evidence base is manufacturer-funded with no long-term safety comparison to the unvaccinated. Confidence: moderate for short-term benefit, low for long-term safety.